NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) issued its earnings results on Thursday, November, 14th. The biotechnology company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.25) by $1.69. The biotechnology company earned $0.97 million during the quarter, compared to the consensus estimate of $4.22 million. Jaguar Health had a negative return on equity of 675.03% and a negative net margin of 771.25%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

2 Wall Street analysts have issued 1 year target prices for Jaguar Health's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Jaguar Health's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 354.1% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

Media stories about JAGX stock have trended very negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jaguar Health earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Jaguar Health.

Some companies that are related to Jaguar Health include Adamas Pharmaceuticals (ADMS), Sierra Oncology (SRRA), Menlo Therapeutics (MNLO), AcelRx Pharmaceuticals (ACRX), Corvus Pharmaceuticals (CRVS), Savara (SVRA), Selecta Biosciences (SELB), Cassava Sciences (SAVA), TapImmune (MRKR), Verastem (VSTM), Avenue Therapeutics (ATXI), Zynerba Pharmaceuticals (ZYNE), Galmed Pharmaceuticals (GLMD), Strongbridge Biopharma (SBBP) and Evelo Biosciences (EVLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Conatus Pharmaceuticals (CNAT), Biopharmx (BPMX), Cara Therapeutics (CARA), Neovasc (NVCN), Precipio (PRPO), PTC Therapeutics (PTCT), Cascadian Therapeutics (CASC), Biocept (BIOC), Cellectar Biosciences (CLRB) and FuelCell Energy (FCEL).

(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $0.88.

Jaguar Health has a market capitalization of $45.05 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.